Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
REC-4881 by Recursion Pharmaceuticals for Colorectal Cancer: Likelihood of Approval
REC-4881 is under clinical development by Recursion Pharmaceuticals and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...